211 results on '"Purkayastha D"'
Search Results
2. Sustainable waste management using black soldier fly larva: a review
3. Name-Based Service Function Forwarder (nSFF) Component within a Service Function Chaining (SFC) Framework
4. Delayed Carotid Surgery: What Are the Causes in the North West of England?
5. What are the Risk Factors for Renal Failure following Open Elective Abdominal Aortic Aneurysm Repair?
6. MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure
7. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study
8. Policy brief. Finding the gap: addressing the international migration data gaps
9. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study
10. Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension
11. Sustainable waste management using black soldier fly larva: a review
12. Antihypertensive Response to Thiazide Diuretic or Angiotensin Receptor Blocker in Elderly Hypertensives Is Not Influenced by Pretreatment Plasma Renin Activity
13. Authorsʼ reply: Logistic risk model for mortality following elective abdominal aortic aneurysm repair
14. Logistic risk model for mortality following elective abdominal aortic aneurysm repair
15. Identifying the risk of renal failure following elective AAA repair: 064
16. Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension
17. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial – a primary care, type 2 diabetes study
18. Gaps in Migration Research. Review of migration theories and the quality and compatibility of migration data on the national and international level
19. The design of an observational study of hypertension management, adherence and pressure control in Blood Pressure Success Zone Program participants
20. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes
21. Identification of symbol digit modality test score extremes in Huntington's disease
22. Do ENT surgeons know their drugs?
23. Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus
24. Firm-specific advantages, multinational joint ventures, and host country tariff policy
25. 147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN)
26. S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW-UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES
27. Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
28. Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
29. PRO3 SUCCESSOR STUDY: TREATMENT AND HEALTH CARE RESOURCE UTILIZATION BY SICKLE CELL PATIENTS WHO PARTICIPATED IN THE SUSTAIN STUDY IN THE UNITED STATES
30. Radius: Midostaurin (mido) Plus Standard of Care (SOC) after Allogeneic Stem Cell Transplant (alloSCT) in Patients (pts) with FLT3-Internal Tandem Duplication (ITD)–Mutated Acute Myeloid Leukemia (AML)
31. Abstract P6-18-25: First-line treatment with ribociclib and letrozole in advanced breast cancer: First interim data from US patients enrolled in the phase 3b CompLEEment-1 clinical trial
32. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor
33. A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
34. Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2.
35. Abstract P5-21-27: Efficacy and safety of ribociclib plus letrozole in US patients enrolled in the MONALEESA-2 study
36. Abstract PD5-11: Not presented
37. Abstract P4-10-07: Patient-centered initiatives for improving trial participation of diverse patient populations in the open-label phase 3b compLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2- advanced breast cancer
38. MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure
39. H17 Huntington's Disease And Forensic Risk Factors In Females
40. Response to Letter to the Editor Re “What are the Risk Factors for Renal Failure Following Open Elective Abdominal Aortic Aneurysm Repair?”
41. HOME AND CLINIC BP RESPONSES IN ELDERLY INDIVIDUALS WITH SYSTOLIC HYPERTENSION DURING INITIAL TREATMENT WITH COMBINED ANGIOTENSIN RECEPTOR BLOCKER+DIURETIC COMPARED TO MONOTHERAPY: PP.27.85
42. COMBINATION ALISKIREN+AMLODIPINE IS MORE EFFECTIVE THAN AMLODIPINE MONOTHERAPY IN MALE AND FEMALE AFRICAN AMERICAN SUBJECTS WITH STAGE 2 HYPERTENSION: PP.5.186
43. COMBINED ALISKIREN+HYDROCHLOROTHIAZIDE PROVIDES IMPROVED BLOOD PRESSURE CONTROL VS RAMIPRIL IN OBESE, STAGE 2 HYPERTENSIVE PATIENTS, REGARDLESS OF BASELINE SYSTOLIC BLOOD PRESSURE: PP.5.189
44. COMBINATION ALISKIREN+AMLODIPINE PROVIDES GREATER BLOOD PRESSURE REDUCTION THAN AMLODIPINE ALONE IN AFRICAN AMERICANS WITH STAGE 2 HYPERTENSION AND OBESITY OR METABOLIC SYNDROME: PP.5.173
45. ANTIHYPERTENSIVE EFFICACY OF COMBINATION ALISKIREN/HYDROCHLOROTHIAZIDE COMPARED TO RAMIPRIL MONOTHERAPY IN OBESE, STAGE 2 HYPERTENSIVE PATIENTS, STRATIFIED BY AGE: PP.5.193
46. INITIAL COMBINED VALSARTAN/HCTZ THERAPY VS EITHER COMPONENT AS MONOTHERAPY IN ELDERLY INDIVIDUALS WITH SYSTOLIC HYPERTENSION: AGE-STRATIFIED ANALYSIS OF THE VALVET STUDY: PP.27.87
47. COMBINATION ALISKIREN+HYDROCHLOROTHIAZIDE DECREASES PLASMA RENIN ACTIVITY AND OXIDATIVE STRESS VERSUS RAMIPRIL WHILE REDUCING BLOOD PRESSURE IN OBESE, STAGE 2 HYPERTENSIVE PATIENTS: PP.5.188
48. EFFICACY AND TOLERABILITY OF COMBINED ANGIOTENSIN RECEPTOR BLOCKER+DIURETIC THERAPY VS COMPONENT MONOTHERAPIES IN ELDERLY INDIVIDUALS WITH SYSTOLIC HYPERTENSION:RESULTS FROM VALVET: PP.27.93
49. ALISKIREN+AMLODIPINE COMBINATION REDUCES CENTRAL BLOOD PRESSURE MORE THAN AMLODIPINE ALONE IN AFRICAN AMERICANS WITH STAGE 2 HYPERTENSION: PP.5.171
50. EFFECT OF VALSARTAN, HYDROCHLOROTHIAZIDE, AND ITS COMBINATION ON 24-HOUR AMBULATORY BLOOD PRESSURE RESPONSE IN ELDERLY INDIVIDUALS WITH SYSTOLIC HYPERTENSION: A VALVET SUBSTUDY: PP.27.96
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.